Skip to main content

Table 1 Patients characteristics and biochemical parameters

From: Bone fragility in sarcoidosis and relationships with calcium metabolism disorders: a cross sectional study on 142 patients

Women/men (number of patients) -80/62
Menopausal women (number of patients) 51/80
Age (years) 51.6 ± 11.6
Mean disease duration (years) 9.5 ± 7.1
BMI (mean ± SD) 27.5 ± 5.4
Radiological Stage I/ II/ III/IV/ (number of patients) 15/69/14/41
Dyspnoea Stage NYHA I and II/ NYHA III and IV (number of patients) 118/45
History of low energy fracture (number of patients) 21
Current CS intake (mean dose): 88 patients 12.4 ± 11.8 mg
Mean cumulative CS dose per patient 27.6 ± 19.9 g
Vitamin D supplements (mean dose) in the six months before the study: 31 patients 181,161 ± 137,430 U
BP treatment (mean treatment duration) before study: 46 patients 25.3 ± 26.7 months
Mean serum 25(OH)D level (N >30 ng/ml) 14.5 ± 7.61
Mean serum 1,25(OH)2D level (66 < N <167 pmol/l) 137.4 ± 50.3
Mean serum PTH level (10 < N <70 pmol/l) 45.36 ± 31.4
Mean creatinine clearance (ml/min) 110.7 ± 35.9
Mean serum calcium level (2.2 < N <2.6 mmol/l) 2.35 ± 0.9
Mean ESR (mm/h) 17.6 ± 14.5
Mean CRP (mg/L) 7.0 ± 9.8
Mean ACE (19 < N <41) 51.7
  1. ACE, angiotensin-converting enzyme; BMI, Body mass index; BP, bisphosphonates; CRP, C-reactive protein; CS, Corticosteroids; ESR, erythrocyte sedimentation rate; NYHA, New York Heart Association; PTH, parathyroid hormone.